Posted by Michael Wonder on 28 Oct 2021
Spero Therapeutics submits new drug application to U.S. FDA for tebipenem hydrobromide for the treatment of complicated urinary tract infections including pyelonephritis
28 October 2021 - Spero Therapeutics today announced the submission of a new drug application to the U.S. FDA, seeking approval for tebipenem hydrobromide tablets for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible microorganisms.
If approved, tebipenem hydrobromide would be the only oral carbapenem antibiotic available for use in cUTI.
